ArticleFrontiers in pharmacology2022

Pan-cancer analyses identify DCBLD2 as an oncogenic, immunological, and prognostic biomarker.

Pan Xie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.